321 related articles for article (PubMed ID: 10574576)
1. Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats.
Thomsen JS; Mosekilde LI; Gasser JA
Bone; 1999 Nov; 25(5):561-9. PubMed ID: 10574576
[TBL] [Abstract][Full Text] [Related]
2. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34).
Kneissel M; Boyde A; Gasser JA
Bone; 2001 Mar; 28(3):237-50. PubMed ID: 11248653
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone increases vertebral and femoral bone strength in osteopenic, ovariectomized, aged rats in a dose-dependent and site-specific manner.
Mosekilde L; Thomsen JS; Orhii PB; Kalu DN
Bone; 1998 Oct; 23(4):343-52. PubMed ID: 9763146
[TBL] [Abstract][Full Text] [Related]
4. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
[TBL] [Abstract][Full Text] [Related]
5. Bone responses at various skeletal sites to human parathyroid hormone in ovariectomized rats: effects of long-term administration, withdrawal, and readministration.
Kishi T; Hagino H; Kishimoto H; Nagashima H
Bone; 1998 May; 22(5):515-22. PubMed ID: 9600786
[TBL] [Abstract][Full Text] [Related]
6. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.
Mosekilde L; Danielsen CC; Søgaard CH; McOsker JE; Wronski TJ
Bone; 1995 Feb; 16(2):223-30. PubMed ID: 7756051
[TBL] [Abstract][Full Text] [Related]
7. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.
Sato M; Zeng GQ; Turner CH
Endocrinology; 1997 Oct; 138(10):4330-7. PubMed ID: 9322947
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia.
Mosekilde L; Tornvig L; Thomsen JS; Orhii PB; Banu MJ; Kalu DN
Bone; 2000 Jun; 26(6):643-51. PubMed ID: 10831937
[TBL] [Abstract][Full Text] [Related]
9. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
[TBL] [Abstract][Full Text] [Related]
10. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
11. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Jee WS; Sato M
J Bone Miner Metab; 2005; 23 Suppl():62-8. PubMed ID: 15984416
[TBL] [Abstract][Full Text] [Related]
13. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats.
Mosekilde L; Danielsen CC; Gasser J
Endocrinology; 1994 May; 134(5):2126-34. PubMed ID: 8156913
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model.
Søgaard CH; Mosekilde L; Thomsen JS; Richards A; McOsker JE
Bone; 1997 May; 20(5):439-49. PubMed ID: 9145241
[TBL] [Abstract][Full Text] [Related]
15. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates.
Søgaard CH; Wronski TJ; McOsker JE; Mosekilde L
Endocrinology; 1994 Feb; 134(2):650-7. PubMed ID: 8299562
[TBL] [Abstract][Full Text] [Related]
16. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
Baumann BD; Wronski TJ
Bone; 1995 Feb; 16(2):247-53. PubMed ID: 7756054
[TBL] [Abstract][Full Text] [Related]
17. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
18. Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat.
Hodsman AB; Watson PH; Drost D; Holdsworth D; Thornton M; Hock J; Bryant H; Fraher LJ
Bone; 1999 May; 24(5):451-5. PubMed ID: 10321904
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
[TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Iwaniec UT; Mosekilde L; Mitova-Caneva NG; Thomsen JS; Wronski TJ
Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
